Skip to main content
Boryung Corporation logo

Boryung Corporation — Investor Relations & Filings

Ticker · 003850 ISIN · KR7003850005 KO Manufacturing
Open in API
Filings indexed 354 across all filing types
Latest filing 2020-05-21 Major Shareholding Noti…
Country KR South Korea
Listing KO 003850

About Boryung Corporation

https://pharm.boryung.co.kr/eng/index.do

Boryung Corporation is a fully integrated healthcare company founded in 1957. Its core business encompasses the research, development, manufacturing, and global commercialization of pharmaceutical products, with a significant presence in the cardiovascular therapeutic area. The company is distinguished by its pioneering 'Care in Space' (CIS) initiative, which focuses on developing healthcare solutions for humans in extreme environments and leveraging space for new research opportunities. In addition to its pharmaceutical operations, Boryung functions as a healthcare investment company, fostering innovation across the health sector. The company's diverse portfolio includes prescription drugs, over-the-counter products, and a pipeline aimed at addressing future medical needs.

Recent filings

Filing Released Lang Actions
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a 'Report of Large Shareholding' (주식등의 대량보유상황보고서), which is a regulatory filing required under the Capital Markets Act in South Korea when a person or entity acquires a significant stake (typically 5% or more) in a listed company. This document details the shareholding status, changes in ownership, and the purpose of the holding. In the context of the provided filing categories, this fits the definition of a 'Major Shareholding Notification' (MRQ).
2020-05-21 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Regulatory Filings Classification · 95% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서). This is a standard regulatory filing in South Korea (DART system) used by insiders or major shareholders to disclose changes in their shareholdings. Since the document details specific share transactions by a major shareholder (Boryung Holdings) and does not fit into the other categories like 'Director's Dealing' (which is usually for individual directors) or 'Major Shareholding Notification' (which is for 5% rule filings), it is best classified as a Regulatory Filing (RNS) as it is a mandatory disclosure of ownership status.
2020-05-21 Korean
최대주주등소유주식변동신고서
Share Issue/Capital Change Classification · 95% confidence The document is a 'Report on Changes in Shareholding by Major Shareholders' (최대주주등소유주식변동신고서) filed by Boryung Pharmaceutical. This type of filing is a regulatory requirement in South Korea to disclose changes in the ownership stakes of major shareholders, including corporate entities and executives. Since it specifically details changes in share ownership levels and major shareholding status, it falls under the 'Major Shareholding Notification' category.
2020-05-20 Korean
유상증자또는주식관련사채등의발행결과(자율공시)
Share Issue/Capital Change Classification · 100% confidence The document is a formal regulatory filing from Boryung Pharmaceutical regarding the results of a capital increase (paid-in capital increase/share issuance). It details the number of shares issued, the amount raised, and the payment date. This falls under the category of share issuance or capital changes.
2020-05-19 Korean
분기보고서 (2020.03)
Interim / Quarterly Report Classification · 100% confidence The document is a '분기보고서' (Quarterly Report) for Boryung Pharmaceutical Co., Ltd. for the period of 2020-01-01 to 2020-03-31. It contains detailed financial statements, management discussion and analysis, and corporate governance information, which aligns with the definition of an Interim/Quarterly Report (IR). Q1 2020
2020-05-15 Korean
주요사항보고서(유상증자결정)
Share Issue/Capital Change Classification · 100% confidence The document is a 'Major Matters Report' (주요사항보고서) filed with the Financial Services Commission and Korea Exchange, specifically detailing a 'Decision on Paid-in Capital Increase' (유상증자결정). This document outlines the issuance of new shares, the purpose of capital raising, the method (third-party allocation), and the pricing details. In the context of Korean corporate filings, this is a regulatory disclosure regarding capital structure changes, which falls under the 'Share Issue/Capital Change' category.
2020-05-11 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.